Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs Sorafenib in Advanced HCC
NCT01004003Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2009
- Primary completion
- Jul 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of nintedanib in hepatocellular carcinoma (HCC), sponsored by Boehringer Ingelheim. Started Oct 2009; status: completed.
02
Drugs
nintedanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01004003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004003.